US Patent
US7576061 — Methods for preventing mitochondrial permeability transition
Composition of Matter · Assigned to Institut de Recherches Cliniques de Montreal IRCM · Expires 2027-01-20 · 1y remaining
Vulnerability score
35/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects a method of reducing or preventing mitochondrial permeability transition by administering an aromatic-cationic peptide.
USPTO Abstract
The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.